NO20074188L - Prosess for fremstilling av montelukast og mellomprodukter for det - Google Patents

Prosess for fremstilling av montelukast og mellomprodukter for det

Info

Publication number
NO20074188L
NO20074188L NO20074188A NO20074188A NO20074188L NO 20074188 L NO20074188 L NO 20074188L NO 20074188 A NO20074188 A NO 20074188A NO 20074188 A NO20074188 A NO 20074188A NO 20074188 L NO20074188 L NO 20074188L
Authority
NO
Norway
Prior art keywords
montelukast
intermediates
manufacturing
compound
formula
Prior art date
Application number
NO20074188A
Other languages
English (en)
Norwegian (no)
Inventor
Arjanne Overeem
Lambertus Thijs
Petr Benovsky
Jakub Castulik
Jie Zhu
Petr Bartos
Radomir Skoumal
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20074188L publication Critical patent/NO20074188L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/75—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20074188A 2005-11-18 2007-08-15 Prosess for fremstilling av montelukast og mellomprodukter for det NO20074188L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73775205P 2005-11-18 2005-11-18
US79442906P 2006-04-24 2006-04-24
US82438206P 2006-09-01 2006-09-01
PCT/EP2006/011127 WO2007057225A2 (en) 2005-11-18 2006-11-20 Process for making montelukast and intermediates therefor

Publications (1)

Publication Number Publication Date
NO20074188L true NO20074188L (no) 2008-08-13

Family

ID=37685804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074188A NO20074188L (no) 2005-11-18 2007-08-15 Prosess for fremstilling av montelukast og mellomprodukter for det

Country Status (12)

Country Link
US (5) US7476748B2 (es)
EP (3) EP1960362A1 (es)
JP (1) JP2009515922A (es)
AR (3) AR056815A1 (es)
AT (1) ATE497493T1 (es)
AU (3) AU2006314728A1 (es)
CA (3) CA2629840A1 (es)
DE (1) DE602006019979D1 (es)
IL (1) IL185129A0 (es)
NO (1) NO20074188L (es)
PT (1) PT1954679E (es)
WO (3) WO2007057225A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831171A4 (en) * 2004-11-19 2010-09-15 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
CN101213177A (zh) 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
EP2014650A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process and intermediate for the production of an intermediate in the production of montelukast
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
TWI450275B (zh) * 2010-05-19 2014-08-21 Wistron Corp 可提升寫入保護之記憶體系統及相關方法
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199796B (en) * 1985-08-06 1990-03-28 Boehringer Biochemia Srl Process for producing 2-thiomethyl-substituted-1,4-dihydropyridines and pharmaceutical compositions comprising such compounds
CA2038178A1 (en) 1990-04-05 1991-10-06 Carl C. Greco Niobium alkoxyalkoxides and process for formation
ES2114882T3 (es) 1990-10-12 1998-06-16 Merck Frosst Canada Inc Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5565473A (en) 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
TW416948B (en) 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5869673A (en) * 1997-02-28 1999-02-09 Merck & Co., Inc. Process for 3-(2-(7-chloro-2-quinolinyl)ethenyl) - benzaldehyde
CN1420113A (zh) 2001-11-16 2003-05-28 北京上地新世纪生物医药研究所 孟鲁司特钠的制备方法及其制备中间体
CN1171873C (zh) * 2001-12-26 2004-10-20 北京上地新世纪生物医药研究所 一种孟鲁司特钠的制备方法及其制备中间体
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST

Also Published As

Publication number Publication date
AR057909A1 (es) 2007-12-26
PT1954679E (pt) 2011-05-05
EP1954679B1 (en) 2011-02-02
AU2006314729A1 (en) 2007-05-24
AR057908A1 (es) 2007-12-26
DE602006019979D1 (de) 2011-03-17
US20070135642A1 (en) 2007-06-14
CA2598093A1 (en) 2007-05-24
EP1954679A1 (en) 2008-08-13
US7786138B2 (en) 2010-08-31
WO2007057228A1 (en) 2007-05-24
CA2629840A1 (en) 2007-05-24
US20070135480A1 (en) 2007-06-14
US7601741B2 (en) 2009-10-13
WO2007057227A1 (en) 2007-05-24
WO2007057225A2 (en) 2007-05-24
ATE497493T1 (de) 2011-02-15
EP1948610A2 (en) 2008-07-30
WO2007057225A3 (en) 2007-07-26
IL185129A0 (en) 2007-12-03
AR056815A1 (es) 2007-10-24
US20070135643A1 (en) 2007-06-14
JP2009515922A (ja) 2009-04-16
US20090093636A1 (en) 2009-04-09
US20100099879A1 (en) 2010-04-22
AU2006314728A1 (en) 2007-05-24
EP1960362A1 (en) 2008-08-27
CA2629834A1 (en) 2007-05-24
AU2006314726A1 (en) 2007-05-24
US7476748B2 (en) 2009-01-13

Similar Documents

Publication Publication Date Title
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
NO20054852L (no) GFAT inhibitorer
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
MY141194A (en) Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
NO20074642L (no) Fremgangsmate for a lage trans-1-((1R,3S)-6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
NO20050921L (no) Nye fysiologisk aktive substanser
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
TW200728307A (en) Novel spirochromanone derivatives
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
EA200701358A1 (ru) Кристаллические формы гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1h-3-бензазепина
NO20073416L (no) Indoler nyttig i behandlingen av inflammasjon
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
TN2009000484A1 (en) Substituted oxazolidinones and the use thereof
NO20054669L (no) Substituerte kinobenzoxazinanaloger
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
NO20082096L (no) Azaindol-2-karboksamidderivativer
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application